Welcome to our dedicated page for Immucell news (Ticker: ICCC), a resource for investors and traders seeking the latest updates and insights on Immucell stock.
ImmuCell Corporation (Nasdaq: ICCC) is an animal health company that develops, manufactures and markets scientifically proven and practical products to improve the health and productivity of dairy and beef cattle. News about ImmuCell often centers on sales performance for its First Defense® product line, strategic decisions regarding its Re-Tain® mastitis treatment candidate, and updates on manufacturing capacity and financing.
Investors following ICCC news can expect regular preliminary, unaudited product sales updates shortly after quarter-end, followed by detailed unaudited financial results releases. These announcements typically include commentary on product sales trends for First Defense®, including Tri-Shield® and Dual-Force® variants, domestic and international sales mix, gross margin performance, and the impact of prior production backlogs and inventory rebuilding.
Company news also covers strategic shifts, such as ImmuCell’s decision to focus resources on expanding the First Defense® franchise after receiving an FDA Incomplete Letter for the Re-Tain® New Animal Drug Application. Releases describe plans to increase the First Defense® sales force, expand manufacturing capacity, repurpose assets, and complete investigational Re-Tain® studies to support potential licensing or partnership opportunities.
Additional ICCC news items include leadership changes, such as the selection and onboarding of a new President and CEO, bank debt refinancing transactions, extensions of credit facilities, and details of conference calls with investors. For readers tracking ICCC, this news feed provides a centralized view of operational updates, product development milestones, capital structure developments and management commentary related to ImmuCell’s cattle health business.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q4 and full-year 2025. Q4 product sales were $7.6 million (down 1.6% year-over-year) with domestic $7.0M (+8.7%), international $0.62M (-52.6%), Tri-Shield $6.0M (+41.3%) and Dual-Force/other $1.7M (-53.0%). FY 2025 sales were $27.6M (+4.3%) with Tri-Shield $19.9M (+26.5%) and Dual-Force $7.7M (-28.2%).
The company received an FDA Incomplete Letter for Re-Tain (Dec 23, 2025), paused further Re-Tain investment and expects an approx. $2.9M non-cash impairment for Re-Tain assets and total Q4 write-downs of $3.6M. Management plans to repurpose most Re-Tain assets for First Defense and expand the sales force by 50%.
ImmuCell (Nasdaq: ICCC) will hold an investor conference call on Friday, January 9, 2026 at 9:00 AM ET to discuss its strategic shift in focus to the First Defense product line and away from Re-Tain, plus unaudited topline sales for the quarter and year ended December 31, 2025. The company will release those topline sales after market close on Thursday, January 8, 2026.
ImmuCell also plans to release full unaudited financial results for the quarter and year on Wednesday, February 25, 2026 with a follow-up call on Thursday, February 26, 2026 at 9:00 AM ET. Dial-in numbers and replay access codes are provided for both calls.
ImmuCell (Nasdaq: ICCC) received an FDA Incomplete Letter for its Re-Tain NADA on December 23, 2025 after four of five technical sections were deemed complete and the contract manufacturer failed to satisfactorily address inspectional deficiencies. ImmuCell will pause further investment in Re-Tain, complete ongoing investigational studies, and pursue licensing or partnering options that avoid further capital or in-house manufacturing expenditure.
ImmuCell is simultaneously increasing First Defense field sales by 50%, expanding First Defense manufacturing, and expects a ~$2.3 million estimated non-cash impairment in Q4 2025 (Re-Tain net book value was $15.5M as of Sept 30, 2025). First Defense reported $27.8M TTM revenue and holds a 29% U.S. spend share in scour prevention; company estimates a $900M worldwide TAM for scours prevention.
ImmuCell (Nasdaq: ICCC) reported unaudited results for the quarter ended September 30, 2025. Q3 product sales fell 8% to $5.5M, while nine-month product sales rose 7% to $20.0M and twelve-month sales rose 16% to $27.8M. The company posted net income of $1.8M for the nine months versus a loss of $2.7M year-ago, driven by higher sales and margin recovery.
Gross margin improved to 42.6% for the nine months (vs. 27.3% prior year). Adjusted EBITDA was $751k for Q3 and $4.42M for nine months. Balance sheet highlights: cash $3.9M, net working capital $12.8M, stockholders' equity $29.8M. Re-Tain remains in investigational use with Michigan State University while management addresses prior backlog.
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter ended September 30, 2025 after market close on Thursday, November 13, 2025. The company plans a conference call to review results on Friday, November 14, 2025 at 9:00 AM ET, accessible by dialing (844) 855-9502 (U.S.) or (412) 317-5499 (international). A teleconference replay will be available through November 21, 2025 using access code 7664668.
The company anticipates no change to preliminary third-quarter sales disclosed on October 7, 2025 and expects to file its Form 10-Q after market close on November 13, 2025. An updated corporate presentation will be posted under the Investors tab at www.immucell.com after the market close on November 13, 2025.
ImmuCell (Nasdaq: ICCC) announced leadership changes effective November 1, 2025: Olivier te Boekhorst began serving as President and CEO, succeeding Michael F. Brigham. At its October 29, 2025 meeting the board also appointed Timothy C. Fiori, who joined as CFO in April 2025, to the Board; Fiori will serve as CFO, Treasurer and Secretary.
Mr. Brigham will remain a board member and act as Special Advisor to the CEO through January 2026. The company plans a conference call on November 14, 2025 at 9:00 AM ET to discuss unaudited Q3 results and expects an updated corporate slide deck after market close on November 13, 2025.
ImmuCell (Nasdaq: ICCC) reported preliminary, unaudited product sales for Q3 2025 and comparable periods. Q3 2025 sales were $5.5 million versus $6.0 million in Q3 2024. Year-to-date trends show $20.0 million for nine months and a trailing twelve-month total of $27.8 million, up from $23.8 million a year earlier.
Management attributes higher prior-period volume to distributor inventory rebuilds, warned of a second-half 2025 sales softening, noted a Non‑Administrative NADA submission in early January 2025, and began investigational use of Re‑Tain through year-end 2025 (not expected to generate revenue).
ImmuCell Corporation (Nasdaq: ICCC) has announced the appointment of Olivier te Boekhorst as its new President and CEO, effective November 1, 2025. Te Boekhorst, currently an Operating Partner at ARCHIMED and Chair of SeqCenter's Board, brings extensive industry experience from his 18-year tenure at IDEXX Laboratories, where he led significant growth initiatives in livestock diagnostics.
The transition includes current President and CEO Michael F. Brigham serving as Special Advisor for at least two months, while maintaining his Board position. Te Boekhorst's compensation package includes two stock option grants - an initial 76,673 shares at $5.90 per share and a subsequent grant of up to 85,000 shares, both vesting over three years.
ImmuCell Corporation (Nasdaq: ICCC) reported strong financial results for Q2 2025, with product sales increasing 18% to $6.4 million compared to Q2 2024. The company achieved significant improvements in profitability, posting net income of $502,000 ($0.06 per share) in Q2 2025, compared to a net loss of $1.5 million in Q2 2024.
Key financial metrics include gross margin improvement to 44% in Q2 2025 (up from 22% in Q2 2024), and cash position strengthening to $6.0 million as of June 30, 2025. The company has eliminated its order backlog and is building inventory for the peak selling season. Regarding Re-Tain®, ImmuCell has initiated Investigational Product use while reducing development expenses and exploring strategic options.
The company's stockholders' equity increased to $29.9 million, and Adjusted EBITDA improved to $1.4 million for the quarter.ImmuCell Corporation (Nasdaq: ICCC) has successfully refinanced its bank debt with Maine Community Bank (MCB). The company secured a new $2.33 million loan at 6.5% interest, which was used to pay off two existing loans: a $1.53 million MCB loan at 7% and a $768,209 FAME loan at 8%.
The refinancing eliminates approximately $1.95 million in balloon payments due in Q3 2026, extending the amortization schedule through Q3 2030. This move strengthens ImmuCell's financial position while maintaining its relationship with MCB. The company, which develops and manufactures health products for dairy and beef cattle, will discuss its Q2 2025 financial results in an upcoming conference call on August 15, 2025.
FAQ
What is the current stock price of Immucell (ICCC)?
What is the market cap of Immucell (ICCC)?
